Fundie reveals why the Pro Medicus (ASX:PME) share price is still a buy

Fund manager Ben Griffiths from Eley Griffiths Group thinks that the Pro Medicus Ltd (ASX:PME) share price is still a buy.

| More on:
a doctor looking up at question marks

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Pro Medicus Ltd (ASX: PME) share price is still a buy according to fund manager Ben Griffiths from the funds management business Eley Griffiths Group.

Why Eley Griffiths is worth listening to

Eley Griffiths runs two funds, The Small Companies Fund and The Emerging Companies Funds.

The Small Companies Fund targets businesses outside of the S&P/ASX 100 Index (ASX: XTO). After fees, it has outperformed the S&P/ASX Small Ord Accumulation Index by an average of 4.2% per annum since inception in September 2003.

What's Pro Medicus?

It's a business that is a health imaging technology provider, predominately in the radiology software and services space for hospitals, imaging centres and health care groups worldwide. It offers an end-to-end offering with its Visage technology.

Fund manager Ben Griffiths explained on Livewire Markets that radiologists and other medical imaging professionals use Visage to interpret images created by medical imaging equipment such as X-Ray, Ultrasound, CT and MRI Scanners.

Why does Eley Griffiths think that the Pro Medicus share price is an opportunity?

The fund manager said that its research shows that Pro Medicus is significantly ahead of its peers when it comes to viewer speed and efficiency for clinics.

One of the highlights for Mr Griffiths is that the healthcare ASX share has been winning contracts worth $155 million in the financial year to date. This has been much stronger than FY19 and FY20 where the wins amounted to around $50 million per annum in those years.

Since 31 December, Pro Medicus has won some very big contracts. One is a 7-year, $40 million contract with US-based Intermountain Healthcare, which operates in the mountain states of Utah, Idaho and Nevada. It also won a 7-year, $31 million contract with a leading Californian academic health system.

The valuation of Pro Medicus is high, according to Eley Griffiths.

However, it's expected to have 20% compound revenue growth over the next five years. Mr Griffiths noted that Pro Medicus could have earnings before interest and tax (EBIT) margins of around 60% – he said it's in "rarefied air".

One of the other things that the fund manager noted was that Pro Medius has a very high return on invested capital (ROIC) compared to most other ASX shares.

Eley Griffiths is particularly excited by the fact Pro Medicus has plenty of ways that it can invest its capital whilst it wins more market share and attract more customers with an even stronger software offering.

Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and recommends Pro Medicus Ltd. The Motley Fool Australia has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »